Glp-1 receptor agonists in dementia

Abstract

The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.

1 . A method for treating Alzheimer's disease, comprising administering semaglutide to a subject in need thereof. 
     
     
         2 . The method according to  claim 1 , wherein the subject has mild cognitive impairment or mild dementia. 
     
     
         3 . The method according to  claim 1 , wherein the semaglutide is the sole pharmaceutically active ingredient administered to the subject. 
     
     
         4 . The method according to  claim 1 , wherein the semaglutide is administered subcutaneously. 
     
     
         5 . The method according to  claim 1 , wherein the semaglutide is administered orally. 
     
     
         6 . The method according to  claim 1 , wherein the semaglutide is administered in a tablet comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. 
     
     
         7 . The method according to  claim 1 , further comprising administering the semaglutide for at least 12 months. 
     
     
         8 . The method according to  claim 6 , wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate. 
     
     
         9 . The method according to  claim 2 , wherein the subject has mild cognitive impairment. 
     
     
         10 . The method according to  claim 9 , wherein the semaglutide is administered subcutaneously. 
     
     
         11 . The method according to  claim 9 , wherein the semaglutide is administered orally. 
     
     
         12 . The method according to  claim 9 , wherein the semaglutide is administered in a tablet comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. 
     
     
         13 . The method according to  claim 12 , wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate. 
     
     
         14 . The method according to  claim 2 , wherein the subject has mild dementia. 
     
     
         15 . The method according to  claim 14 , wherein the semaglutide is administered subcutaneously. 
     
     
         16 . The method according to  claim 14 , wherein the semaglutide is administered orally. 
     
     
         17 . The method according to  claim 14 , wherein the semaglutide is administered in a tablet comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. 
     
     
         18 . The method according to  claim 17 , wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate. 
     
     
         19 . The method according to  claim 3 , wherein the semaglutide is administered subcutaneously. 
     
     
         20 . The method according to  claim 3 , wherein the semaglutide is administered orally. 
     
     
         21 . The method according to  claim 3 , wherein the semaglutide is administered in a tablet comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. 
     
     
         22 . The method according to  claim 21 , wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate.